WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205856
Description: ME-344 is an active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells. In pre-clinical studies, ME-344 has shown tenfold more anti-tumor activity than NV-128.
MedKoo Cat#: 205856
Chemical Formula: C22H20O4
Exact Mass: 348.13616
Molecular Weight: 348.39
Elemental Analysis: C, 75.84; H, 5.79; O, 18.37
ME-344 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: ME-344; ME 344; ME344.
IUPAC/Chemical Name: 4,4'-(7-hydroxy-8-methylchroman-3,4-diyl)diphenol.
InChi Key: QVCAATSEPLQVBX-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H20O4/c1-13-20(25)11-10-18-21(15-4-8-17(24)9-5-15)19(12-26-22(13)18)14-2-6-16(23)7-3-14/h2-11,19,21,23-25H,12H2,1H3
SMILES Code: CC1=C(O)C=CC2=C1OCC(C3=CC=C(O)C=C3)C2C4=CC=C(O)C=C4
The following data is based on the product molecular weight 348.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lim SC, Carey KT, McKenzie M. Anti-cancer analogues ME-143 and ME-344 exert
toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase
(Complex I). Am J Cancer Res. 2015 Jan 15;5(2):689-701. eCollection 2015. PubMed
PMID: 25973307; PubMed Central PMCID: PMC4396027.